Page 1833 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 106 Haploidentical Hematopoietic Cell Transplantation 1632.e3

86. Yamasaki S, Ohno Y, Taniguchi S, et al: Allogeneic peripheral blood 106. Lu DP, Dong L, Wu T, et al: Conditioning including antithymocyte
stem cell transplantation from two- or three-loci-mismatched related globulin followed by unmanipulated HLA-mismatched/haploidentical
donors in adult Japanese patients with high-risk hematologic malignan- blood and marrow transplantation can achieve comparable outcomes
cies. Bone Marrow Transplant 33(3):279–289, 2004. with HLA-identical sibling transplantation. Blood 107(8):3065–3073,
87. Ciceri F, Labopin M, Aversa F, et al: A survey of fully-haploidentical 2006.
+
hematopoietic stem cells transplantation in adults with high-risk acute 107. Dong L, Wu T, Zhang MJ, et al: CD3 cell dose and disease status are
leukemia: a risk factor analysis of outcomes for patients transplanted in important factors determining clinical outcomes in patients undergoing
remission. Blood 112:3574, 2008. unmanipulated haploidentical blood and marrow transplantation after
88. Lang P, Teltschik HM, Feuchtinger T, et al: Transplantation of CD3/ conditioning including antithymocyte globulin. Biol Blood Marrow
CD19 depleted allografts from haploidentical family donors in paedi- Transplant 13(12):1515–1524, 2007.
atric leukaemia. Br J Haematol 165(5):688–698, 2014. 108. Nachbaur D, Eibl B, Kropshofer G, et al: In vivo T cell depletion with
89. Amrolia PJ, Muccioli-Casadei G, Huls H, et al: Adoptive immunother- low-dose rabbit antithymocyte globulin results in low transplant-related
apy with allodepleted donor T-cells improves immune reconstitution mortality and low relapse incidence following unrelated hematopoietic
after haploidentical stem cell transplantation. Blood 108(6):1797–1808, stem cell transplantation. J Hematother Stem Cell Res 11(4):731–737,
2006. 2002.
90. Bacchetta R, Lucarelli B, Sartirana C, et al: Immunological outcome in 109. Morton J, Hutchins C, Durrant S: Granulocyte-colony-stimulating
haploidentical HSC transplanted patients treated with IL-10-anergized factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-
donor T cells. Front Immunol 5:16, 2014. versus-host disease and comparable engraftment to G-CSF-mobilized
91. Devaud C, Bilhere E, Loizon S, et al: Antitumor activity of γδ T cells peripheral blood stem cells. Blood 98(12):3186–3191, 2001.
reactive against cytomegalovirus-infected cells in a mouse xenograft 110. Chen XH, Gao L, Zhang X, et al: HLA-haploidentical blood and
tumor model. Cancer Res 69(9):3971–3978, 2009. bone marrow transplantation with anti-thymocyte globulin: long-term
92. Scheper W, van Dorp S, Kersting S, et al: γδ T cells elicited by CMV comparison with HLA-identical sibling transplantation. Blood Cells Mol
reactivation after allo-SCT cross-recognize CMV and leukemia. Leuke- Dis 43(1):98–104, 2009.
mia 27(6):1328–1338, 2013. 111. Luo Y, Xiao H, Lai X, et al: T-cell-replete haploidentical HSCT
93. Fujishima N, Hirokawa M, Fujishima M, et al: Skewed T cell receptor with low-dose anti-T-lymphocyte globulin compared with matched
+
repertoire of Vδ1 γδ T lymphocytes after human allogeneic haema- sibling HSCT and unrelated HSCT. Blood 124(17):2735–2743,
topoietic stem cell transplantation and the potential role for Epstein- 2014.
Barr virus-infected B cells in clonal restriction. Clin Exp Immunol 112. Chen H, Liu KY, Xu LP, et al: Haploidentical hematopoietic stem cell
149(1):70–79, 2007. transplantation without in vitro T cell depletion for the treatment of
+
94. Lamb LS, Jr, Musk P, Ye Z, et al: Human γδ T lymphocytes have in Philadelphia chromosome–positive acute lymphoblastic leukemia. Biol
vitro graft vs leukemia activity in the absence of an allogeneic response. Blood Marrow Transplant 21:1110, 2015.
Bone Marrow Transplant 27(6):601–606, 2001. 113. Lee KH, Lee JH, Kim DY, et al: Reduced-intensity conditioning
95. Drobyski WR, Hessner MJ, Klein JP, et al: T-cell depletion plus salvage therapy with busulfan, fludarabine, and antithymocyte globulin for
immunotherapy with donor leukocyte infusions as a strategy to treat HLA-haploidentical hematopoietic cell transplantation in acute leuke-
chronic-phase chronic myelogenous leukemia patients undergoing mia and myelodysplastic syndrome. Blood 118(9):2609–2617, 2011.
HLA-identical sibling marrow transplantation. Blood 94(2):434–441, 114. Chen HR, Ji SQ, Wang HX, et al: Humanized anti-CD25 monoclonal
1999. antibody for prophylaxis of graft-vs-host disease (GVHD) in haploiden-
96. Drobyski WR, Vodanovic-Jankovic S, Klein J: Adoptively transferred γδ tical bone marrow transplantation without ex vivo T-cell depletion. Exp
T cells indirectly regulate murine graft-versus-host reactivity following Hematol 31(11):1019–1025, 2003.
donor leukocyte infusion therapy in mice. J Immunol 165(3):1634– 115. Ji SQ, Chen HR, Yan HM, et al: Anti-CD25 monoclonal antibody
1640, 2000. (basiliximab) for prevention of graft-versus-host disease after haploi-
97. Schumm M, Lang P, Bethge W, et al: Depletion of T-cell receptor α/β dentical bone marrow transplantation for hematological malignancies.
and CD19 positive cells from apheresis products with the CliniMACS Bone Marrow Transplant 36(4):349–354, 2005.
device. Cytotherapy 15(10):1253–1258, 2013. 116. Arcese W, Picardi A, Santarone S, et al: Haploidentical, G-CSF-primed,
98. Bertaina A, Merli P, Rutella S, et al: HLA-haploidentical stem cell unmanipulated bone marrow transplantation for patients with high-
+
transplantation after removal of αβ T and B cells in children with risk hematological malignancies: an update. Bone Marrow Transplant
nonmalignant disorders. Blood 124(5):822–826, 2014. 50(Suppl 2):S24, 2015.
99. Di Ianni M, Falzetti F, Carotti A, et al: Tregs prevent GVHD and 117. Huang XJ, Liu DH, Liu KY, et al: Treatment of acute leukemia with
promote immune reconstitution in HLA-haploidentical transplanta- unmanipulated HLA-mismatched/haploidentical blood and bone
tion. Blood 117(14):3921–3928, 2011. marrow transplantation. Biol Blood Marrow Transplant 15(2):257–265,
100. Martelli MF, Di Ianni M, Ruggeri L, et al: HLA-haploidentical trans- 2009.
plantation with regulatory and conventional T-cell adoptive immuno- 118. Al-Homsi AS, Cole K, Bogema M, et al: Short course of post-
therapy prevents acute leukemia relapse. Blood 124(4):638–644, 2014. transplantation cyclophosphamide and bortezomib for graft-versus-host
101. Leen AM, Christin A, Myers GD, et al: Cytotoxic T lymphocyte disease prevention after allogeneic peripheral blood stem cell transplan-
therapy with donor T cells prevents and treats adenovirus and Epstein- tation is feasible and yields favorable results: a phase I study. Biol Blood
Barr virus infections after haploidentical and matched unrelated stem Marrow Transplant 21(7):1315–1320, 2015.
cell transplantation. Blood 114(19):4283–4292, 2009. 119. Sun YQ, Wang J, Jiang Q, et al: Haploidentical hematopoietic SCT
102. Melenhorst JJ, Castillo P, Hanley PJ, et al: Graft versus leukemia may be superior to conventional consolidation/maintenance chemo-
response without graft-versus-host disease elicited by adoptively trans- therapy as post-remission therapy for high-risk adult ALL. Bone Marrow
ferred multivirus-specific T-cells. Mol Ther 23:179, 2015. Transplant 50:20, 2015.
103. Ciceri F, Bonini C, Stanghellini MT, et al: Infusion of suicide-gene- 120. Huang XJ, Liu DH, Liu KY, et al: Haploidentical hematopoietic stem
engineered donor lymphocytes after family haploidentical haemopoietic cell transplantation without in vitro T-cell depletion for the treatment of
stem-cell transplantation for leukaemia (the TK007 trial): a non- hematological malignancies. Bone Marrow Transplant 38(4):291–297,
randomised phase I–II study. Lancet Oncol 10(5):489–500, 2009. 2006.
104. Di Stasi A, Tey SK, Dotti G, et al: Inducible apoptosis as a safety switch 121. Wang Y, Chang YJ, Xu LP, et al: Who is the best donor for a related
for adoptive cell therapy. N Engl J Med 365(18):1673–1683, 2011. HLA haplotype-mismatched transplant? Blood 124(6):843–850,
105. Ji SQ, Chen HR, Wang HX, et al: G-CSF-primed haploidentical marrow 2014.
transplantation without ex vivo T cell depletion: an excellent alterna- 122. Huo MR, Xu LP, Li D, et al: The effect of HLA disparity on clinical
tive for high-risk leukemia. Bone Marrow Transplant 30(12):861–866, outcome after HLA-haploidentical blood and marrow transplantation.
2002. Clin Transplant 26(2):284–291, 2012.